A study carried out by the Walter Reed Army Institute of Research and GlaxoSmithKline has tested the first in-human vaccine for a Plasmodium vivax malaria vaccine. The study found that the drug could slow the development of the infection in 59% of recipients.
UK pharmaceutical firm Shire has reached a £32bn deal to acquire US rival Baxalta. Shire was interested in Baxalta's pipeline of new treatments, while Baxalta could benefit from Shire's lower corporation tax bill in Dublin.
Australian-based researchers discover that one form of chromium becomes carcinogenic after oxidation's taken place inside cells. Their finding might have deep implications for chromium supplements-takers